Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,028 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.
Verhoek A, Cheema P, Melosky B, Samson B, Shepherd FA, de Marinis F, John T, Wu YL, Heeg B, Van Dalfsen N, Bracke B, Miranda M, Shaw S, Moldaver D. Verhoek A, et al. Among authors: miranda m. Pharmacoecon Open. 2023 May;7(3):455-467. doi: 10.1007/s41669-023-00396-0. Epub 2023 Feb 22. Pharmacoecon Open. 2023. PMID: 36811822 Free PMC article.
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.
Marinis F, Wu YL, de Castro G Jr, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, Provencio M, Vansteenkiste J, Vicente D, Zhou Q, Miranda MF, Bakker NA, Rigas JR, Cheema PK. Marinis F, et al. Among authors: miranda mf. Future Oncol. 2019 Sep;15(26):3003-3014. doi: 10.2217/fon-2019-0324. Epub 2019 Jul 24. Future Oncol. 2019. PMID: 31339357
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL. Papadimitrakopoulou VA, et al. Among authors: miranda m. Ann Oncol. 2020 Nov;31(11):1536-1544. doi: 10.1016/j.annonc.2020.08.2100. Epub 2020 Aug 27. Ann Oncol. 2020. PMID: 32861806 Free article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 39112306
Predicting the Anti-SARS-CoV-2 Potential of Isoquinoline Alkaloids from Brazilian Siparunaceae Species Using Chemometric Tools.
Gomes BA, Fernandes DA, Mendonça SC, Campos MF, da Fonseca TS, Constant LEC, de Sousa NF, Priscila Barros de Menezes R, de Oliveira BAC, da Silva Costa S, Frensel GB, Rosa AS, Oliveira TKF, Tucci AR, Lima JNH, Ferreira VNS, Miranda MD, Allonso D, Scotti MT, Leitão SG, Leitão GG. Gomes BA, et al. Among authors: miranda md. Int J Mol Sci. 2025 Jan 13;26(2):633. doi: 10.3390/ijms26020633. Int J Mol Sci. 2025. PMID: 39859347 Free article.
Muscular Performance and Blood Pressure After Different Pre-Strength Training Strategies in Recreationally Strength-Trained Women: Cross-Over Trial.
Monteiro ER, Pescatello LS, Leitão L, de Miranda MJC, Marchetti PH, Novaes MR, da Silva Araújo G, Corrêa Neto VG, da Silva Novaes J. Monteiro ER, et al. Among authors: de miranda mjc. J Cardiovasc Dev Dis. 2024 Dec 26;12(1):7. doi: 10.3390/jcdd12010007. J Cardiovasc Dev Dis. 2024. PMID: 39852285 Free article.
3,028 results